Gossamer Bio (GOSS) Received its Third Buy in a Row

After Piper Sandler and H.C. Wainwright gave Gossamer Bio (NASDAQ: GOSS) a Buy rating last month, the company received another Buy, this time from SVB Securities. Analyst Joseph Schwartz reiterated a Buy rating on Gossamer Bio yesterday and set a price target of $15.00. The company’s shares closed last Tuesday at $11.99.

According to, Schwartz is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -9.0% and a 36.4% success rate. Schwartz covers the Healthcare sector, focusing on stocks such as Applied Molecular Transport, Ultragenyx Pharmaceutical, and Mereo Biopharma Group Plc.

Gossamer Bio has an analyst consensus of Strong Buy, with a price target consensus of $15.25, a 35.4% upside from current levels. In a report issued on July 13, Piper Sandler also maintained a Buy rating on the stock.

See the top stocks recommended by analysts >>

Gossamer Bio’s market cap is currently $869.9M and has a P/E ratio of -3.63.

Based on the recent corporate insider activity of 16 insiders, corporate insider sentiment is neutral on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Gossamer Bio, Inc. engages in discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. Its primary product candidate is GB001, which is intended for the treatment of moderate-to-severe eosinophilic asthma and other allergic conditions. The company was founded by Faheem Hasnain and Sheila Gujrathi in 2015 and is headquartered in San Diego, CA.

Read More on GOSS:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More